Carbon dioxide test as an additional clinical measure of treatment response in panic disorder

Arq Neuropsiquiatr. 2002 Jun;60(2-B):358-61. doi: 10.1590/s0004-282x2002000300003.

Abstract

Objective: We aim to determine if a treatment with a dose of clonazepam--2 mg/day, for 6 weeks, blocks spontaneous panic attacks and the ones induced by the inhalation of 35% carbon dioxide (CO2) in panic disorder (PD) patients. The CO2 challenge-test may be a useful addition tool for measuring the pharmacological response during the initial phase (6 weeks) in the treatment of PD.

Method: Eighteen PD patients drug free for a week participated in a carbon dioxide challenge test. Fourteen had a panic attack and were openly treated for a 6-week period with clonazepam. At the end of the 6-week period they were submitted again to the CO2 challenge test.

Results: After 6 weeks of treatment with clonazepam, 12 of 14 PD patients (85.7%) did not have a panic attack after the CO2 challenge test. Just 2 of 14 patients (14.3%) had a panic attack after the CO2 challenge test. Ten of 14 (71.4%) PD patients had panic free status after clonazepam treatment. The 2 patients who had a panic attack in the sixth week, after the CO2 test, did not have panic free status after the treatment with clonazepam.

Conclusion: The CO2-test may be a valid tool for testing and predicting the drug response.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Inhalation
  • Adolescent
  • Adult
  • Anticonvulsants / therapeutic use*
  • Benzodiazepines / therapeutic use
  • Breath Tests / methods
  • Carbon Dioxide* / adverse effects
  • Clonazepam / therapeutic use*
  • Double-Blind Method
  • Female
  • Humans
  • Male
  • Middle Aged
  • Panic Disorder / chemically induced
  • Panic Disorder / diagnosis
  • Panic Disorder / drug therapy*
  • Treatment Outcome

Substances

  • Anticonvulsants
  • Benzodiazepines
  • Carbon Dioxide
  • Clonazepam